We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Low Number of Baselines γδ T Cells Increases the Risk of SARS-CoV-2 Post-Vaccination Infection.
- Authors
Andreu-Ballester, Juan Carlos; Galindo-Regal, Lorena; Cuéllar, Carmen; López-Chuliá, Francisca; García-Ballesteros, Carlos; Fernández-Murga, Leonor; Llombart-Cussac, Antonio; Domínguez-Márquez, María Victoria
- Abstract
Background: The COVID-19 pandemic is the biggest global health problem in the last hundred years. The efficacy of the vaccine to protect against severe disease is estimated to be 70–95% according to the studies carried out, although there are aspects of the immune response to the vaccine that remain unclear. Methods: Humoral and cellular immunity after the administration of three doses of the Pfizer–BioNTech and Oxford AstraZeneca vaccines against SARS-CoV-2 over one year and the appearance of post-vaccination COVID-19 were studied. SARS-CoV-2 IgG and IgA antibodies, αβ and γδ T-cell subsets, and their differentiation stages and apoptosis were analyzed. Results: Anti-SARS-CoV-2 IgG and IgA antibodies showed a progressive increase throughout the duration of the study. This increase was the greatest after the third dose. The highest levels were observed in subjects who had anti-SARS-CoV-2 antibodies prior to vaccination. There was an increase in CD4+ αβ, CD8+ γδ and TEM CD8+ γδ T cells, and a decrease in apoptosis in CD4+ CD8+ and CD56+ αβ and γδ T cells. Post-vaccination SARS-CoV-2 infection was greater than 60%. The symptoms of COVID-19 were very mild and were related to a γδ T cell deficit, specifically CD8+ TEMRA and CD56+ γδ TEM, as well as lower pre-vaccine apoptosis levels. Conclusions: The results unveil the important role of γδ T cells in SARS-CoV-2-vaccine-mediated protection from the disease.
- Subjects
T cells; ASTRAZENECA PLC; SARS-CoV-2; VACCINE effectiveness; COVID-19 vaccines; CELLULAR immunity
- Publication
Vaccines, 2024, Vol 12, Issue 5, p553
- ISSN
2076-393X
- Publication type
Article
- DOI
10.3390/vaccines12050553